Monte Rosa Therapeutics, Inc. GLUE Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s pre-tax income?
- Monte Rosa Therapeutics, Inc. (GLUE) reported pre-tax income of -$44.45M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s pre-tax income changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s pre-tax income decreased by 193.2% year-over-year, from $47.71M to -$44.45M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s pre-tax income?
- Over 2 years (2022 to 2025), Monte Rosa Therapeutics, Inc.'s pre-tax income has grown at a -39.5% compound annual growth rate (CAGR), from -$108.5M to -$39.72M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.